Targeting energy metabolism in brain cancer: Review and hypothesis

Nutrition and Metabolism

Volumn 2, Issue , 2005, Pages

  Seyfried, Thomas N ^a   Mukherjee, Purna ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ANTICONVULSIVE AGENT; FREE RADICAL; GLUCOSE; KETONE; STEROID;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ASTROCYTOMA; BIOENERGY; BRAIN CANCER; BRAIN TUMOR; BREATHING; CALORIC INTAKE; CELL SURVIVAL; ENERGY METABOLISM; GENOME; GLIA CELL; GLUCOSE BRAIN LEVEL; GLYCOLYSIS; HUMAN; KETOGENIC DIET; METABOLIC DISORDER; NERVE CELL; REVIEW; TUMOR CELL;

EID: 27744502691     PISSN: 17437075     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-2-30     Document Type: Review

References (111)

1. Kaiser J: No meeting of minds on childhood cancer. Science 1999, 286:1832-1834.
2. Lowry JK, Snyder JJ, Lowry PW: Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998, 55:922-928.
3. Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J: Population-based epidemiologic data on brain tumors in German children. Cancer 2001, 92:3155-3164.
4. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG: Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro-oncol 2001, 3:141-151.
5. Zimmerman HM: The nature of gliomas as revealed by animal experimentation. Amer J Pathol 1955, 31:1-29.
6. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER: Patterns of care for adults with newly diagnosed malignant glioma. Jama 2005, 293:557-564.
7. Fisher PG, Buffler PA: Malignant gliomas in 2005: where to GO from here? Jama 2005, 293:615-617.
8. Seyfried TN: Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect Biol Med 2001, 44:263-282.
9. Sonnenschein C, Soto AM: The Society of Cells: Cancer and the Control of Cell Proliferation. New York: Springer-Verlag; 1999.
10. Shapiro WR: Current therapy for brain tumors: back to the future. Arch Neurol 1999, 56:429-432.
11. Sonnenschein C, Soto AM: Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. Mol Carcinog 2000, 29:205-211.
12. Kiebish MA, Seyfried TN: Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer 2005, 5:102.
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
14. Veech RL: The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004, 70:309-319.
15. Greene AE, Todorova MT, Seyfried TN: Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem 2003, 86:529-537.
16. Veech RL: Metabolic control analysis of ketone and insulin action: Implications for phenotyping of disease and design of therapy. 2002 [http://www.biodynamichealthaging.org/].
17. Strohman R: Maneuvering in the complex path from genotype to phenotype. Science 2002, 296:701-703.
18. Kacser H, Burns JA: The molecular basis of dominance. Genetics 1981, 97:639-666.
19. Greenspan RJ: The flexible genome. Nat Rev Genet 2001, 2:383-387.
20. Seyfried TN, Mukherjee P, Adams E, Mulroony T, Abate LE: Metabolic Control of Brain Cancer: Role of Glucose and Ketone Bodies. Proc Amer Assoc Cancer Res 2005, 46:1147.
21. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P: Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 2003, 89:1375-1382.
22. Kirsch WM, Schulz Q, Van Buskirk J, Nakane P: Anaerobic energy metabolism in brain tumors. Prog Exp Tumor Res 1972, 17:163-191.
23. Mangiardi JR, Yodice P: Metabolism of the malignant astrocytoma. Neurosurgery 1990, 26:1-19.
24. Lichtor T, Dohrmann GJ: Respiratory patterns in human brain tumors. Neurosurgery 1986, 19:896-899.
25. Lowry OH, Passonneau JV, Hasselberger FX, Shulz DW: Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. J Biol Chem 1964, 239:18-30.
26. Clarke DD, Sokoloff L: Circulation and energy metabolism in the brain. In Basic Neurochemistry sixth edition. Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:637-669.
27. Cahill GF Jr: Starvation in man. N Engl J Med 1970, 282:668-675.
28. Ebert D, Haller RG, Walton ME: Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci 2003, 23:5928-5935.
29. Allen NJ, Karadottir R, Attwell D: A preferential role for glycolysis in preventing the anoxic depolarization of rat hippocampal area CA1 pyramidal cells. J Neurosci 2005, 25:848-859.
30. Pellerin L, Pellegri G, Martin JL, Magistretti PJ: Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc Natl Acad Sci U S A 1998, 95:3990-3995.
31. Pellerin L, Bergersen LH, Halestrap AP, Pierre K: Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 2005, 79:55-64.
32. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr: Brain metabolism during fasting. J Clin Invest 1967, 46:1589-1595.
33. VanItallie TB, Nufert TH: Ketones: metabolism's ugly duckling. Nutr Rev 2003, 61:327-341.
34. Morris AA: Cerebral ketone body metabolism. J Inherit Metab Dis 2005, 28:109-121.
35. Cahill GF Jr, Veech RL: Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003, 114:149-161. discussion 162-143
36. Mantis JG, Centeno NA, Todorova MT, McGowan R, Seyfried TN: Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr Metab (Lond) 2004, 1:11.
37. Seyfried TN, Mukherjee P: Anti-Angiogenic and Pro-Apoptotic Effects of Dietary Restriction in Experimental Brain Cancer: Role of Glucose and Ketone Bodies. In Integration/Interaction of Oncologic Growth Volume 15. 2nd edition. Edited by: Meadows GG. New York: Kluwer Academic; 2005.
38. Leino RL, Gerhart DZ, Duelli R, Enerson BE, Drewes LR: Dietinduced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 2001, 38:519-527.
39. Koehler-Stec EM, Simpson IA, Vannucci SJ, Landschulz KT, Landschulz WH: Monocarboxylate transporter expression in mouse brain. Am J Physiol 1998, 275:E516-524.
40. Zhang F, Vannucci SJ, Philp NJ, Simpson IA: Monocarboxylate transporter expression in the spontaneous hypertensive rat: effect of stroke. J Neurosci Res 2005, 79:139-145.
41. Pan JW, de Graaf RA, Rothman DL, Hetherington HP: 13C-[2,4]-b- hydroxybutyrate metabolism in human brain. J Neurochem 2002, 81(suppl 1):45.
42. Fredericks M, Ramsey RB: 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J Neurochem 1978, 31:1529-1531.
43. Bhagavan NV: Medical Biochemistry. Fourth edition. New York: Harcourt; 2002.
44. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr: Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51:241-247.
45. Laterra J, Keep R, Betz AL, Goldstein GW: Blood-brain-cerebrospinal fluid barriers. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects sixth edition. Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:671-689.
46. Fanelli C, Di Vincenzo A, Modarelli F, Lepore M, Ciofetta M, Epifano L, Pampanelli S, Brunetti P, Bolli GB: Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. Diabetologia 1993, 36:1191-1197.
47. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL: D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A 2000, 97:5440-5444.
48. Masuda R, Monahan JW, Kashiwaya Y: D-beta-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures. J Neurosci Res 2005, 80:501-509.
49. Nehlig A, Pereira de Vasconcelos A: Glucose and ketone body utilization by the brain of neonatal rats. Prog Neurobiol 1993, 40:163-221.
50. Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, Chance B, Clarke K, Veech RL: Insulin, ketone bodies, and mitochondrial energy transduction. Faseb J 1995, 9:651-658.
51. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605.
52. Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T: In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983, 14:614-626.
53. Nagamatsu S, Nakamichi Y, Inoue N, Inoue M, Nishino H, Sawa H: Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 1996, 319(Pt 2):477-482.
54. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT: Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003, 61:151-160.
55. Floridi A, Paggi MG, Fanciulli M: Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci 1989, 33:55-64.
56. Galarraga J, Loreck DJ, Graham JF, DeLaPaz RL, Smith BH, Hallgren D, Cummins CJ: Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1986, 1:279-291.
57. Mies G, Paschen W, Ebhardt G, Hossmann KA: Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally-induced glioma (RG1 2.2) of rat brain. J Neurooncol 1990, 9:17-28.
58. Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF: Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 1997, 17:1903-1911.
59. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 1997, 89:1763-1773.
60. Patel MS, Russell JJ, Gershman H: Ketone-body metabolism in glioma and neuroblastoma cells. Proc Natl Acad Sci U S A 1981, 78:7214-7218.
61. Roeder LM, Poduslo SE, Tildon JT: Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res 1982, 8:671-682.
62. Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K: Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res 2004, 24:2213-2217.
63. Tisdale MJ: Role of acetoacetyl-CoA synthetase in acetoacetate utilization by tumor cells. Cancer Biochem Biophys 1984, 7:101-107.
64. Portais JC, Voisin P, Merle M, Canioni P: Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. Biochimie 1996, 78:155-164.
65. Meixensberger J, Herting B, Roggendorf W, Reichmann H: Metabolic patterns in malignant gliomas. J Neurooncol 1995, 24:153-161.
66. Pedersen PL: Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978, 22:190-274.
67. Warburg O: The Metabolism of Tumours. New York: Richard R. Smith; 1931.
68. Warburg O: On the origin of cancer cells. Science 1956, 123:309-314.
69. Cuezva JM, Chen G, Alonso AM, Isidore A, Misek DE, Hanash SM, Beer DG: The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25:1157-1163.
70. Aisenberg AC: The Glycolysis and Respiration of Tumors. New York: Academic Press; 1961.
71. Ikezaki K, Black KL, Conklin SG, Becker DP: Histochemical evaluation of energy metabolism in rat glioma. Neurol Res 1992, 14:289-293.
72. Schlame M, Rua D, Greenberg ML: The biosynthesis and functional role of cardiolipin. Prog Lipid Res 2000, 39:257-288.
73. Canuto RA, Biocca ME, Muzio G, Dianzani MU: Fatty acid composition of phospholipids in mitochondria and microsomes during diethylnitrosamine carcinogenesis in rat liver. Cell Biochem Funct 1989, 7:11-19.
74. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al.: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899.
75. Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995, 14:202-208.
76. Stafstrom CE, Bough KJ: The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci 2003, 6:67-79.
77. Freeman JM, Freeman JB, Kelly MT: The Ketogenic Diet: A Treatment for Epilepsy. third edition. New York: Demos; 2000.
78. Stewart JW, Koehler K, Jackson W, Hawley J, Wang W, Au A, Myers R, Birt DF: Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis 2005, 26:1077-1084.
79. Zhu Z, Jiang W, Thompson HJ: Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Carcinogenesis 2003, 24:1225-1231.
80. Patel NV, Finch CE: The glucocorticoid paradox of caloric restriction in slowing brain aging. Neurobiol Aging 2002, 23:707-717.
81. Mukherjee P, Abate LE, Seyfried TN: Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 2004, 10:5622-5629.
82. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN: Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 2002, 86:1615-1621.
83. Duan W, Lee J, Guo Z, Mattson MP: Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. J Mol Neurosci 2001, 16:1-12.
84. Birt DF, Yaktine A, Duysen E: Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. J Nutr 1999, 129:571S-574S.
85. Spindler SR: Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev 2005.
86. Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP: Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech 2002, 59:264-272.
87. Weindruch R, Walford RL: The retardation of aging and disease by dietary restriction. Springfield, IL: Thomas; 1988.
88. Tannenbaum A: Nutrition and cancer. In Physiopathology of Cancer Edited by: Homburger F. NY: Paul B. Hober; 1959:517-562.
89. Rebrin I, Kamzalov S, Sohal RS: Effects of age and caloric restriction on glutathione redox state in mice. Free Radic Biol Med 2003, 35:626-635.
90. Aronen HJ, Pardo FS, Kennedy DN, Belliveau JW, Packard SD, Hsu DW, Hochberg FH, Fischman AJ, Rosen BR: High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000, 6:2189-2200.
91. Tannenbaum A: The genesis and growth of tumors: II. Effects of caloric restriction per se. Cancer Res 1942, 2:460-467.
92. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK: Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999, 91:512-523.
93. Pennathur S, Ido Y, Heller JI, Byun J, Danda R, Pergola P, Williamson JR, Heinecke JW: Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: A potential pathway for oxidative damage of retinal proteins in diabetes. J Biol Chem 2005.
94. Andersson AK, Ronnback L, Hansson E: Lactate induces tumour necrosis factor-alpha, interleukin-6 and interleukin-1beta release in microglial- and astroglial-enriched primary cultures. J Neurochem 2005, 93:1327-1333.
95. Dong W, Selgrade MK, Gilmour IM, Lange RW, Park P, Luster MI, Kari FW: Altered alveolar macrophage function in calorierestricted rats. Am J Respir Cell Mol Biol 1998, 19:462-469.
96. Potts R: Humanity's Descent: The Consequences of Ecological Instability. New York: William Morrow & Co., Inc; 1996.
97. Harold FM: The Vital Force: A Study of Bioenergetics. New York: W. H. Freeman; 1986.
98. Albers RW, Siegel GJ: Membrane transport. In Basic Neurochemistry sixth edition. Edited by: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:95-118.
99. Lipton P, Robacker K: Glycolysis and brain function: [K+]o stimulation of protein synthesis and K+ uptake require glycolysis. Fed Proc 1983, 42:2875-2880.
100. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, Imura H, Shigemoto R, Kikuchi H: Distribution of the glucose transporters in human brain tumors. Cancer Res 1992, 52:3972-3979.
101. Boado RJ, Black KL, Pardridge WM: Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 1994, 27:51-57.
102. Strohman R: Thermodynamics - old laws in medicine and complex disease. Nat Biotechnol 2003, 21:477-479.
103. Nebeling LC, Lerner E: Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 1995, 95:693-697.
104. Covarrubias DJ, Rosen BR, Lev MH: Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004, 9:528-537.
105. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004, 324:269-275.
106. Fearon KC: Nutritional pharmacology in the treatment of neoplastic disease. Baillieres Clin Gastroenterol 1988, 2:941-949.
107. Sokoloff B, Eddy WH, Saelof CC, Beach J: Glucose antagonists in experimental cancer. Arch Pathol .
108. Magee BA, Potezny N, Rofe AM, Conyers RA: The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci 1979, 57:529-539.
109. Landau BR, Laszlo J, Stengle J, Burk D: Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958, 21:485-494.
110. Cleary MP, Jacobson MK, Phillips FC, Getzin SC, Grande JP, Maihle NJ: Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiol Biomarkers Prev 2002, 11:836-843.
111. Meadows GG, Fu Y-M: Dietary restriction of specific amino acids modulates tumor and host interactions. In Integration/Interaction of Oncologic Growth Volume 15. 2nd edition. Edited by: Meadows GG. New York: Kluwer Academic; 2005.